Jim Gaffigan isn't ashamed to admit he jumped on the weight-loss medication bandwagon. In a new interview, the comedian ...

Jim Gaffigan has a sleek new look to match his recent Hollywood renaissance, which includes his hilarious turn on SNL as vice ...

The recently appointed Trump adviser is "getting a little big for his britches" according to insiders The post Chris Hayes ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

Jim Gaffigan reveals his weight loss journey with Mounjaro tackling food addiction and societal stigma while balancing comedy ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.